Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Aug;79(15):4696-700.
doi: 10.1073/pnas.79.15.4696.

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects

S C Rall Jr, K H Weisgraber, T L Innerarity, R W Mahley

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects

S C Rall Jr et al. Proc Natl Acad Sci U S A. 1982 Aug.

Abstract

The three major isoforms of human apolipoprotein E (apo-E2, -E3, and -E4) are coded for by three alleles (epsilon 2, epsilon 3, and epsilon 4) which have a common genetic locus. Previously, we demonstrated that E2, E3, and E4 differ in primary structure from one another at two substitution sites, site A (residue 112) and site B (residue 158). At sites A/B, apo-E2, -E3, and -E4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively. We demonstrated that the substitution of cysteine for arginine at site B is at least partly responsible for the defective binding of apo-E2 to human fibroblast low density lipoprotein receptors, compared to the normal binding activity of apo-E3 or -E4. Subjects with the genetic disorder type III hyperlipoproteinemia are phenotypically homozygous for apo-E2, but the binding activity of apo-E to the fibroblast receptor differs considerably from one type III individual to another. We therefore undertook a partial comparative sequence analysis of apo-E2 from three type III subjects whose apo-E displayed this heterogeneity. The subject with the poorest binding apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cysteine was found at sites A and B. The subject with the most active apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cystine was found at site A and at a new site (site C, residue 145). The epsilon 2 allele specifies a protein that has arginine at site B (residue 158); the epsilon 2 allele specifies a protein that has arginine at site C (residue 145). Therefore, the two alleles differ from one another by cysteine/arginine interchanges at two positions, sites B and C. The third subject, whose apo-E2 displayed binding activity intermediate between the activities of the other two, was genotypically heterozygous, having one epsilon 2 allele and one epsilon 2 allele. The intermediate binding activity of apo-E2 from this subject resulted from having a mixture of severely defective apo-E (specified by epsilon 2) and slightly defective apo-E (specified by epsilon 2).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis.
    Sadeghi HM, Sabzghabaee AM, Mousavian Z, Saadatnia M, Shirani S, Moazen F. Sadeghi HM, et al. J Res Med Sci. 2011 Dec;16(12):1519-24. J Res Med Sci. 2011. PMID: 22973358 Free PMC article.
  • The impact of low-frequency and rare variants on lipid levels.
    Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Steinthorsdottir V, Tobin MD, Tsernikova N, van Leeuwen EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Metspalu A, Slagboom PE, Groop L, van Duijn CM, Eriksson JG, Jula A, Salomaa V, Boomsma DI, Power C, Raitakari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lindgren CM, Stefansson K, Palotie A, McCarthy MI, Morris AP, Prokopenko I, Ripatti S; ENGAGE Consortium. Surakka I, et al. Nat Genet. 2015 Jun;47(6):589-97. doi: 10.1038/ng.3300. Epub 2015 May 11. Nat Genet. 2015. PMID: 25961943 Free PMC article.
  • Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E.
    Vogel T, Weisgraber KH, Zeevi MI, Ben-Artzi H, Levanon AZ, Rall SC Jr, Innerarity TL, Hui DY, Taylor JM, Kanner D, et al. Vogel T, et al. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8696-700. doi: 10.1073/pnas.82.24.8696. Proc Natl Acad Sci U S A. 1985. PMID: 3909150 Free PMC article.
  • Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    Le Guen Y, Raulin AC, Logue MW, Sherva R, Belloy ME, Eger SJ, Chen A, Kennedy G, Kuchenbecker L, O'Leary JP, Zhang R, Merritt VC, Panizzon MS, Hauger RL, Gaziano JM, Bu G, Thornton TA, Farrer LA, Napolioni V, He Z, Greicius MD. Le Guen Y, et al. JAMA. 2023 Feb 21;329(7):551-560. doi: 10.1001/jama.2023.0268. JAMA. 2023. PMID: 36809323 Free PMC article.
  • Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.
    Havel RJ, Kotite L, Kane JP, Tun P, Bersot T. Havel RJ, et al. J Clin Invest. 1983 Jul;72(1):379-87. doi: 10.1172/jci110978. J Clin Invest. 1983. PMID: 6860421 Free PMC article.
See all "Cited by" articles

References

    1. FEBS Lett. 1975 Aug 15;56(2):352-5 - PubMed
    1. J Lipid Res. 1977 Sep;18(5):613-22 - PubMed
    1. Biochemistry. 1978 Apr 18;17(8):1440-7 - PubMed
    1. Clin Genet. 1979 Jan;15(1):37-62 - PubMed
    1. J Biol Chem. 1979 May 25;254(10):4186-90 - PubMed

Substances

LinkOut - more resources